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Abstract
Background: Mild traumatic brain injury (TBI) is associated with substantial costs due to over-triage of patients
to computed tomography (CT) scanning, despite validated decision rules. Serum biomarker S100B has shown
promise for safely omitting CT scans but the economic impact from clinical use has never been reported. In
2007, S100B was adapted into the existing Scandinavian management guidelines in Halmstad, Sweden, in an
attempt to reduce CT scans and save costs.
Methods: Consecutive adult patients with mild TBI (GCS 14-15, loss of consciousness and/or amnesia), managed with
the aid of S100B, were prospectively included in this study. Patients were followed up after 3 months with a
standardized questionnaire. Theoretical and actual cost differences were calculated.
Results: Seven hundred twenty-six patients were included and 29 (4.7 %) showed traumatic abnormalities on
CT. No further significant intracranial complications were discovered on follow-up. Two hundred twenty-nine
patients (27 %) had normal S100B levels and 497 patients (73 %) showed elevated S100B levels. Over-triage
occurred in 73 patients (32 %) and under-triage occurred in 39 patients (7 %). No significant intracranial
complications were missed. The introduction of S100B could save 71 € per patient if guidelines were strictly
followed. As compliance to the guidelines was not perfect, the actual cost saving was 39 € per patient.
Conclusion: Adding S100B to existing guidelines for mild TBI seems to reduce CT usage and costs, especially
if guideline compliance could be increased.
Background
Head injury is a serious health problem in developed
countries and associated with a substantial economic
burden [1]. Most (up to 95 %) of head injuries are classi-
fied as mild head injury (MHI), commonly defined as
Glasgow Coma Scale (GCS) 13-15 with the presence of
certain risk factors such as loss of consciousness (LOC)
and/or amnesia [2, 3].
Typical management of MHI involves computed
tomography (CT) of the brain to identify complications
such as intracranial haemorrhage and cerebral contusions
[4]. These complications are rare but may occasionally
need neurosurgical intervention [5]. Guidelines have
therefore recommended liberal CT examinations in this
patient group. Patients with GCS 15 and no risk factors
have a very low risk of intracranial complication [6] and
can be discharged from the emergency department (ED)
without a CT scan [7].
Due to the considerable resource use and high number
of unnecessary CT scans, recent efforts have been
concentrated on optimizing CT use after MHI [7–12].
These decision rules are based upon risk factors from
patient history and clinical examination. However, due
to the high socioeconomic cost of missing cases of
intracranial complication, CT rates remain high [12].
Another aspect to be taken into account is the logistics
of patients waiting in the ED to have a CT scan. Some
departments may obtain a CT result within minutes but
in smaller facilities patients may need to wait several
hours before a CT can be carried out, stocking the work
flow at the ED [12].
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Several groups have considered the use of brain bio-
marker S100B in this clinical setting. Studies show that
serum levels of the protein may reduce CT scans in
the MHI subgroup of patients by 30 % without missing
intracranial complications [13–15]. Serum levels of S100B
are also not affected by ethanol intoxication [16] and
represent an objective addition to the more subjective risk
factors included in existing guidelines. Despite theoretical
reports of the potential of S100B to reduce costs in this
patient group, no reports of clinical S100B use, and hence
actual cost and time reduction, exist.
In the year 2000, the Scandinavian Neurotrauma
Committee (SNC) published guidelines for management
of non-severe head injuries [7]. In 2007, serum S100B
measurements were introduced into these guidelines at
Halmstad Regional Hospital, Sweden, based upon the
evidence available at the time, in an attempt to reduce
CT scans, costs and waiting time in the ED. The aim of
the present study was to establish if this change in
management routines resulted in a decrease in health
care costs and waiting time for patients.
Methods
Study setting and population
The study setting is the Halmstad Regional hospital,
Sweden; a level II trauma centre with 24-h emergency
care, anaesthesiology, radiology, surgery and intensive
care. From November 2007 (6 months following the
introduction of S100B into clinical care, see Fig. 1 for
management routines) to December 2013 we prospectively
Fig. 1 modified Scandinavia Neurotrauma Committee guidelines including S100B sampling
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enrolled consecutive adult patients with MHI and
S100B sampling, according to these clinical guidelines.
In September 2013, an update to the Scandinavian
Guidelines was introduced. This study did not take
into account the new guidelines and age or antiplatelet
medications were not considered as risk factors. The
inclusion criteria in this study were: adult patients with
acute trauma to the head with GCS 14-15 during exami-
nation and/or loss of consciousness for less than 5 min
with no neurological deficits nor additional risk factors
(therapeutic anticoagulation or haemophilia, clinical signs
of depressed skull fracture or skull base fracture, posttrau-
matic seizures, shunt-treated hydrocephalus and multiple
injuries). According to SNC guidelines, trauma history
was not considered as a risk factor.
Exclusion criteria were: age less than 18 years, non-
Swedish citizens (difficult to follow up) and patients
where serum sampling for S100B was done more than
3 h post-injury.
Ethical approval was granted from the regional ethics
board (approval number 19/2007).
S100B analysis
A 5 ml blood sample was drawn from patient’s cubital
vein in the ED. Samples were analysed with the fully
automated Elecsys® S100 (Roche AB) at the Clinical
Chemistry Department of Halmstad Regional hospital,
Sweden, with results being available to treating phy-
sicians within 1 h. Based on previous studies [13, 14],
we set a cut-off level for normal levels of S100B at less
than 0.10 μg/L and a window of sampling of within 3 h
from the time of the accident.
CT examinations
CT scans were performed with a GE VCT Ligthspeed 64
multislice CT scanner including 10 mm thick slices.
CT scans are always analysed by a board certified
radiologist.
Data registration and follow-up
Details of how patients were managed, including patient
characteristics, injury type, patient history, clinical
examination results, current medications, CT details
including time needed from the writing of the request
to the radiologist result, admission type and duration
were documented in a pre-determined database.
Compliance to the guidelines was calculated by exam-
ining the actual patient management compared to the
suggested management from the guidelines. All patients
were asked to answer a questionnaire sent by mail
3 months after the injury. The questionnaire was repeated
if no answer was received. If no answer was received
from these attempts, patients were contacted via tele-
phone. Included in this questionnaire were questions
that would identify a significant intracranial lesion [9],
occupation, data concerning sick-days, new contacts
with medical professionals and information concerning
functionality and quality of life. In cases where patients
could not be reached by mail or telephone, medical
records and national mortality databases were consulted
for evidence of complications and/or death. Patients
who would suffer significant (enough to seek medical
care) intracranial complications after discharge would
therefore be identified.
Data was registered on an Excel® file. Descriptive
statistics was analysed using IBM SPSS® Statistics
Version 20 software. Comparison of number of sick days
between the two groups of patients was performed with
the non-parametric Mann–Whitney U-test.
Cost analysis
The Swedish health care is state-owned; it is partially
difficult to determine the costs on an individual basis
considering that state refund of hospital expenses are
based on hospital annual budget more than refund
per service. Our cost analysis is therefore based upon
standard costs according to our hospital accounts or
(where data is missing) national reports. The average
cost for S100B analysis during the study period was
21€ and the average cost for a non-contrast cranial
CT was 130€. The cost of one day in the surgery ward
(the typical admission ward for MHI patients) was 600€.
Using data from the OCTOPUS study [4], the costs
for a patient that is admitted only for MHI observation
was calculated to be 61 % of the total costs, i.e. 366€
a day. We decided not to calculate a monetary value
regarding the opportunity costs related to time spent by
patients in the ED (difficult to assess) and we did not
consider socioeconomic costs associated with increased
cancer risks from CT scans at all (theoretically based).
Not considering these aspects would lead to an
under-estimation of the cost-saving potential of S100B
implementation.
Results
We enrolled 795 patients with MHI and S100B levels.
Sixty-nine patients were excluded according to exclusion
criteria: 15 patients were younger than 18 years of age,
45 patients did not live in Sweden, 9 patients had their
S100B blood sampling more than 3 h post-injury. The
final population was therefore 726 patients. Descriptive
statistics are presented in Table 1.
Compliance to guidelines was reasonable; more than
67 % of patients were managed according to guidelines.
Two hundred twenty-nine patients had a S100B lower
than 0.10 μg/L and among them 156 patients (68 %)
were directly discharged without a CT or being admitted
for in-hospital observation (Fig. 2). Even among patients
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with elevated S100B levels, we registered cases of poor
compliance to the guidelines where patients with normal
CT were admitted to hospital or patients with normal
12-24 h in hospital observation still underwent a CT
scan (121 patients) (Fig. 2).
Thirty- two patients had pathology on CT but only 29
of these (4.7 %) were classed as traumatic abnormalities
(isolated skull fracture n = 4, cerebral contusions n = 9,
acute subdural hematoma n = 3, intracranial air n = 2,
combinations of traumatic intracranial findings n = 11).
No patients needed neurosurgical intervention. One
patient with a small cerebral contusion was dismissed
without hospitalization. One patient died as a result of
the head injury; an 83-year-old male with expansive
cerebral contusions that later resulted in a fatal intracra-
nial pressure increase. He had an admission S100B level
of 0.23 μg/L. Details of how patients were managed are
presented in Fig. 2.
The follow up questionnaire was completed for 589
patients (81 %), consisting of 190 patients with normal
S100B levels (83 % of population with normal S100B
levels) and 399 patients with elevated S100B levels (80 %
of population with elevated S100B levels). No patient
with negative S100B levels sought the emergency room
for missed complications. In the questionnaire, patients
reported number of sick-days; there was no significant
difference in number of sick-days between patients
with normal S100B levels and those with elevated
levels (p = 0.352).
Average waiting time to CT was 4 h and 14 min,
calculated from the 398 patients that underwent a CT
examination, with a waiting time range from 1 h and
35 min to 8 h and 35 min (Fig. 3).
The actual cost were calculated for the 726 patients
strictly taking into account only S100B analysis, CT and
hospitalisation cost, for an average of 242 € per patient.
To calculate the potential reduction in cost, we calcu-
lated several potential costs given different assumptions
(Table 2): 1) potential cost if S100B is not used in the
guidelines and assuming the same practices regarding
CT and hospitalization for all patients as for the 570
patients that had high S100B levels in the actual cohort
(281 € per patient), and 2) potential cost if the guidelines
with S100B are followed strictly and assuming that only
CT is used, as recommended in the guidelines, for the
497 patients with S100B levels higher than 0.10 ug/L
(110 €). If the guidelines were followed strictly and CT
Table 1 Descriptive statistics
S100B < 0.10 μg/L S100B≥ 0.10 μg/L All
Male 140 (61.1 %) 305 (61.3 %) 445 (61.3 %)
Female 89 (38.9 %) 192 (38.7 %) 281 (38.7 %)





Alcohol intoxication 94 (41 %) 231 (46.4 %) 325 (44.7 %)
Total 229 497 726
Fig. 2 Patients management in the study cohort including number of intracranial injuries. CT = computed tomography; MHI = mild head injury
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only was used as the management option, the potential
savings per patient was 71 € for this cohort. Given the
actual use of S100B and CT/ hospitalization for our
cohort, the calculated savings was limited to 39 € per
patient.
Discussion
Considering the scarcity of health care resources,
socioeconomic aspects of patient management should
be fundamental [12, 17]. MHI is a common reason
for ED contact and is associated with considerable
use of health care resources [17]. These are partly
due to the ineffective triage of patients to either discharge
or further examinations/admission. However, these
routines have been warranted due to the significant
consequences of missing a significant brain injury after
MHI for both patients and health care providers [18].
Although several rules have been suggested in MHI
management, they are only based upon positive predic-
tors, i.e. risk factors that should lead to a CT scan if
present. The decision to incorporate S100B into the
existing SNC guidelines in our hospital in 2007 was
based upon the negative predictive ability of this bio-
marker, i.e. an aspect that could potentially reduce
resource use. Since 2007, additional studies and a meta-
analysis have confirmed findings showing the potential
of S100B to safely reduce CT scans in this patient
group [19–21].
Fig. 3 Time to CT-result (hours)
Table 2 Actual cost for 726 patients = cost for S100B + cost for all the CT taken + cost for all the patients hospitalized
S100 = 21 € CT = 130 € Hospitalization = 366 € Tot
ACTUAL COST in follow-up
(cost per patient)




S100B not in guidelines and
assuming same use of CT
and hospitalization as for
cohort
0,7 x 726 x 130 €= 66 066 € 0,52 x 726 x 366 €= 138 172 € 204 238 €
(281€)
Strict compliance based on
guidelines for S100 + CT only
726 × 21 € = 15 246 € CT (S100B+)
497 × 130€ = 64 610 €
79 856 €
(110 €)
Potential cost for 726 patients given different assumptions:
-if S100B is not included in guidelines= 156 patients with S100B negative were directly dismissed, we calculated an hypothetical cost if they underwent a CT or
were hospitalized
-strict compliance based on guidelines= we considered that all the patients with a negative S100B were dismissed (138 patients) and took into account only the
cost for S100 B positive patients
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Our findings show a reduction in costs after S100B
implementation in a typical ED setting. However,
compliance to the new guidelines regarding S100 and
use of CT and hospitalization was not perfect and
both over- and under-triage was observed. Since the
routines were relatively new (we allowed 6 months before
initiating the study) it is understandable that physicians
over-triaged patients with normal S100B levels. None
of these showed any intracranial complications.
It is important that guidelines in this setting show a
very high sensitivity (high negative predictive value) for
significant intracranial injuries. The cost of missing a
patient with such a complication is substantial [18]. Even
though we have included over 700 patients in our study,
a much larger cohort would be needed to include
enough patients with significant complications to clearly
examine this aspect. However, it may be unreasonable to
expect 100 % sensitivity in a guideline and clinical advice
and/or follow-up should be included in order to identify
and treat patients missed from the initial triage [11].
Adapting our results into other cohorts may be diffi-
cult. Firstly, adapting S100B into guidelines other than
the SNC proposal will naturally show different results.
However, independent economic and clinical compa-
risons of the most prominent decision rules have shown
the SNC guidelines to be similar, if not superior, in
performance [8, 12, 22]. Despite this, validation and cost
analysis of clinical S100B use in other guidelines using
other cohorts are naturally warranted. Also, costs for the
different aspects of the management routines will differ
between sites. Caregivers should, however, be able to
adapt their costs into our results to give an estimation of
the economic impact our management routines in other
health care systems. Finally, our results are based upon
some assumptions regarding the use of CT and/or
hospitalization. The guidelines recommend CT as the
primary management option. However, our results show
that many patients were hospitalized, sometimes in
addition to CT scanning. Our assumptions therefore
also included a model including the use of CT and hospi-
talisation that was observed in the present cohort.
Conclusion
Adding S100B to existing guidelines as a negative
predictor for normal CT scans is potentially cost saving,
although actual savings will ultimately be determined by
compliance to guidelines and local costs for CT and
hospitalisation.
The biomarker should be considered as a clinical tool,
especially when CT rates of MHI patients are high.
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